Glaxosmithkline Pharma Ltd


BSE: 500660 | NSE: GLAXO | ISIN: INE159A01016 
Market Cap: [Rs.Cr.] 16,730 | Face Value: [Rs.] 10
Industry: Pharmaceuticals - Multinational

 Discuss this stock

Board Meet

07-May-12 
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 07, 2012, inter alia, to consider & approval of unaudited financial results for the quarter ended March 31, 2012. 
16-Feb-12 
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 16, 2012, inter alia, to consider approval of audited financial result for the year ended December 31, 2011 and to recommend dividend, if any, on the equity shares of the Company. GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 16, 2012, inter alia, recommended a dividend of Rs. 45/- per equity share for the year ended December 31, 2011. (As Per BSE Announcement Dated on 16.02.2012) 
04-Nov-11 
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 04, 2011, inter alia, to consider approval of unaudited financial results for the quarter ended September 30, 2011 (Q3). GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors at its Meeting held on November 04, 2011, have appointed Mr. A. N. Roy as Additional Non-Executive Independent Director, with effect from November 04, 2011. (As Per BSE Announcement Website dated on 07.11.2011) 
10-Aug-11 
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 10, 2011, inter alia, to consider amongst other things, approval of unaudited financial results for the quarter April - June 2011 (Q2) and half-year January - June 2011. 
06-May-11 
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 06, 2011, inter alia, to consider, approval of unaudited financial results for the quarter ended March 31, 2011 (Q1). 

AGM

29-Mar-11
Glaxosmithkline Pharmaceuticals Limited has submitted to the Exchange a copy of notice of the Annual General Meeting of the Company to be held on March 29, 2011. GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the members at the 86th Annual General Meeting (AGM) of the Company held on March 29, 2011, inter alia, have accorded to the following: 1. Approval of Directors Report, the Auditors Report, the Audited Profit & Loss Account for the year ended December 31, 2010 and the Balance Sheet as at that date. 2. Declaration of dividend for the year ended December 31, 2010 at the rate of Rs. 40.00 per share for the year ended December 31, 2010. 3. Re-appointment of Mr. P. V. Nayak. Mr. V. Narayanan & Mr. D. Sundaram as Directors of the Company liable to retire by rotation. 4. Re-appointment of M/s. Price Waterhouse & Co., as Statutory Auditors of the Company (including all its branches) to hold office from the conclusion of this Meeting until the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions. 5. Re-appointment of Mr. M. B. Kapadia as Whole-time Director of the Company for the period from May 01, 2011 to September 30, 2014, on necessary terms & conditions. 6. Re-appointment of Dr. A. Banerjee as Whole-time Director of the Company for the period from August 01, 2011 to July 31, 2012, on necessary terms & conditions. (As Per BSE Announcement Website dated on 29.04.2011) 
25-Mar-10
Glaxosmithkline Pharmaceuticals Limited has submitted to the Exchange a copy of notice of the Annual General Meeting of the members to be held on March 25, 2010. GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the members at the 85th Annual General Meeting (AGM) of the Company held on March 25, 2010, inter alia, have accorded to the following: 1. Approval of Audited Annual Accounts for the year ended December 31, 2009 and the Report of Auditors and Directors thereon. 2. Approval of the declaration of Dividend of Rs. 30/- per Equity share. 3. Re-appointment of Mr. R. R. Bajaaj, Mr. M. B. Kapadia & Mr. R. C, Sequeira as Directors of the Company liable to retire by rotation. 4. Re-appointment of M/s. Price Waterhouse & Co., as Statutory Auditors of the Company. 5. Appointment of Mr. A. M. Nimbalkar who was an Additional Director, as an Independent Director of the Company. 6. Amendment of Articles of Association of the Company in order to increase the strength of the Board of Directors from twelve to fifteen. (As Per BSE Announcement Website dated on 26.03.2010) GlaxoSmithKline Pharmaceuticals Ltd has submitted to BSE a copy of the minutes of the Annual General Meeting (AGM) held on March 25, 2010. (As Per BSE Announcement Dated on 28/04/2010) 
02-Apr-09
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the members at the 84th Annual General Meeting (AGM) of the Company held on April 02, 2009, inter alia, have accorded to the following: 1. Adoption of the Directors' Report, the Auditors' Report, the Audited Profit & Loss Account for the year ended December 31, 2008 and the Balance Sheet as at that date. 2. Declaration of dividend at the rate of Rs 22.00 per share and absorbing Rs 186.35 crores and a special dividend of Rs 18.00 per share and absorbing Rs 152.46 crores out of the profits of the Company for the year ended December 31, 2008 on 8,47,03,017 equity shares. 3. Re-appointment of Dr. A Banerjee, Mr. N Kaviratne & Mr. R R Bajaaj, as Directors of the Company. 4. Re-appointment of M/s. Price Waterhouse & Co, Chartered Accountants, as Auditors of the Company (including all its branches) to hold office from the conclusion of this Meeting until the conclusion of the next Annual General Meeting of the Company, on remuneration terms & conditions. 5. Re-appointment of Dr. A Baner as the Whole-time Director of the Company for a period from January 01,2009 to July 31, 2011, on remuneration terms & conditions. 
30-Mar-07
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the members at the 82nd Annual General Meeting (AGM) of the Company held on March 30, 2007, inter alia, have accorded to the following: 1. Adoption of the Directors Report, the Auditors Report, the Audited Profit & Loss Account for the year ended December 31, 2006 and the Balance Sheet as at that date. 2. Declaration of dividend at the rate of Rs 17.00 per share for the year ended December 31, 2006 and a special additional dividend of Rs 14.00 per share for the year ended on December 31, 2006 on equity shares. 3. Re-appointment of Mr. R R Bajaaj, Dr. A Banerjee & Mr. M B Kapadia as Directors of the Company. 4. Re-appointment of M/s. Price Waterhouse & Co., Chartered Accountants, as Auditors of the Company (including all its branches) to hold office from the conclusion of this meeting until the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions. 5. Appointment of Dr. H B Joshipura as the Managing Director of the Company for a period of five years with effect from January 01, 2007, on remuneration, terms & conditions. 6. Re-appointment of Mr. M B Kapadia as Whole-time Director of the Company for a period of five years with effect from May 01, 2006, on remuneration terms & conditions. 
12-Apr-06
Glaxosmithkline Pharmaceuticals Limited has submitted to the Exchange a copy of the Minutes of the AGM of the Company held on April 12, 2006.  

EGM

No EGM Data Found!

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Glaxosmit Pharma 16,729.94 26.48 8.71 23.27 30.7 47.7 0.00
Sanofi India 4,742.45 26.25 4.29 16.19 18.2 27.0 0.00
Astrazeneca Phar 4,731.88 239.29 25.00 27.64 31.7 49.8 0.00
Pfizer 3,471.44 18.78 2.66 8.63 15.7 24.0 0.00
Abbott India 3,066.27 26.10 5.63 14.58 28.3 42.4 0.00
Novartis India 2,298.72 15.01 3.27 8.97 22.6 33.8 0.00
Wyeth 1,972.10 13.63 4.04 6.89 37.4 53.1 0.01
Merck 962.14 18.12 2.35 8.45 16.8 25.3 0.00
Fulford (India) 246.48 0.00 1.64 12.29 1.2 1.9 0.00
Organon (India) 159.14 0.00 0.98 0.00 15.3 22.8 0.00

Futures & Options Quote

 
Expiry Date
NA
Instrument: NA
Expiry Date: NA
Strike Price: NA
Open Price: NA
Average Price: NA
No. of Contracts Traded: NA
Open Interest: NA
Underlying: NA
Option Type: NA
Market Lot: NA
Previous Close: NA
Day’s High | Low: NA | NA
Turnover (Cr.): NA
Open Int. Change: NA | NA
View detailed F& O quotes >>

Key Information

Key Executives:

D S Parekh , Chairman 

V Thyagarajan , Vice Chairman 

H B Joshipura , Managing Director 

R R Bajaaj , Director 


Company Head Office / Quarters:
GSK House,
Dr Annie Besant Road Worli,
Mumbai,
Maharashtra-400030
Phone : 91-022-24959595
Fax : 91-022-24959494
E-mail : ajay.a.nadkarni@gsk.com
Web : http://www.gsk-india.com
Registrars:
Karvy Computershare Pvt Ltd
Plot No 17-24
Vittal Rao Nagar
Madhapur
Hyderabad-500081

Calendar

May-2012
M T W T F S S
21 22 23 24 25 26 27
IPO
listNo IPO today
Economic Events
list U. of Michigan Confidence
list Italian Hourly Wages (MoM)
Results
list Reliance Infra. | Crompton Greaves | ITC | Guj Fluorochem